Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 245-249

  Matsumoto, Hirofumi ^a   Sakamoto, Atsuhiko ^a   Fujiwara, Masachika ^a   Yano, Yukiko ^b   Shishido Hara, Yukiko ^a   Fujioka, Yasunori ^a   Kamma, Hiroshi ^a  

^a KYORIN UNIVERSITY   (Japan)

^b ITO HOSPITAL   (Japan)

Author keywords

Cyclic AMP; Growth suppression; Mitogen activated protein kinase phosphorylation; Thyroid papillary carcinoma cells

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; B RAF KINASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN PATCHED; PROTEIN RET; RAP1 PROTEIN;

ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA;

EID: 69249141121     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Marshall CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
2. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, van de Woude GF and Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994. (Pubitemid 24281496)
3. Abe Y, Ichikawa Y, Muraki T, Ito K and Homma M: Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab 52: 23-28, 1981. (Pubitemid 11217834)
4. Sheils OM and Sweeney EC: TSH receptor status of thyroid neoplasms - TaqMan RT-PCR analysis of archival material. J Pathol 188: 87-92, 1999.
5. Vassart G and Dumont JE: The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 13: 596-611, 1992.
6. Iyengar R: Gating by cyclic AMP: expanded role for an old signaling pathway. Science 271: 461-463, 1996.
7. Medina DL and Santisteban P: Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Eur J Endocrinol 143: 161-178, 2000.
8. Kimura T, van Keymeulen A, Golstein J, Fusco A, Dumont JE and Roger PP: Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22: 631-656, 2001. (Pubitemid 32955247)
9. Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, Izumi M and Nagataki S: Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 75: 596-602, 1992.
10. Derwahl M, Kuemmel M, Goretzki P, Schatz H and Broecker M: Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP. Biochem Biophys Res Commun 191: 1131-1138, 1993. (Pubitemid 23231607)
11. Hishinuma A, Yamanaka T, Kasai K, So S, Bamba N and Shimoda SI: Growth regulation of the human papillary thyroid cancer cell line by protein tyrosine kinase and cAMP-dependent protein kinase. Endocr J 41: 399-407, 1994. (Pubitemid 24297497)
12. Ohta K, Pang XP, Berg L and Hershman JM: Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82: 2633-2638, 1997. (Pubitemid 27337885)
13. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K and Uchida K: Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep 18: 441-445, 2007.
14. Hoelting T, Tezelman S, Siperstein AE, Duh QY and Clark OH: Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation. Biochem Biophys Res Commun 195: 1230-1236, 1993. (Pubitemid 23290286)
15. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216-222, 2006. (Pubitemid 43740191)
16. Dumaz N and Marais R: Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the special FEBS meeting in Brussels. FEBS J 272: 3491-3504, 2005.
17. Stork PJ and Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266, 2002. (Pubitemid 34634174)
18. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R and Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580, 2003. (Pubitemid 36920701)
19. Hordijk PL, Verlaan I, Jalink K, van Corven EJ and Moolenaar WH: cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J Biol Chem 269: 3534-3538, 1994. (Pubitemid 2045156)
20. Burgering BM, Pronk GJ, van Weeren PC, Chardin P and Bos JL: cAMP antagonizes p21ras-directed activation of extracellular signal-regulated kinase 2 and phosphorylation of mSos nucleotide exchange factor. EMBO J 12: 4211-4220, 1993. (Pubitemid 23302035)
21. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R and Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 90: 10300-10304, 1993. (Pubitemid 23328300)
22. Sevetson BR, Kong X and Lawrence JC Jr: Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 90: 10305-10309, 1993. (Pubitemid 23328301)
23. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ and Sturgill TW: Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262: 1065-1069, 1993. (Pubitemid 24035048)
24. Vossler MR, Yao H, York RD, Pan MG, Rim CS and Stork PJ: cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82, 1997. (Pubitemid 27180587)
25. Cook SJ and McCormick F: Inhibition by cAMP of Ras-dependent activation of Raf. Science 262: 1069-1072, 1993.
26. Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M, Philipp A and Kolch W: Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol 16: 5409-5418, 1996. (Pubitemid 26315060)
27. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM and Gutmann DH: Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem 274: 25842-25848, 1999. (Pubitemid 129530763)
28. Schmitt JM and Stork PJ: Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol Cell Biol 21: 3671-3683, 2001.
29. Lee TH, Chuang LY and Hung WC: Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 18: 4269-4274, 1999.
30. L'Allemain G, Lavoie JN, Rivard N, Baldin V and Pouyssegur J: Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene 14: 1981-1990, 1997.
31. Heinrich R and Kraiem Z: The protein kinase A pathway inhibits c-jun and c-fos protooncogene expression induced by the protein kinase C and tyrosine kinase pathways in cultured human thyroid follicles. J Clin Endocrinol Metab 82: 1839-1844, 1997.
32. Bakiri L, Lallemand D, Bossy-Wetzel E and Yaniv M: Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 19: 2056-2068, 2000. (Pubitemid 30237581)
33. Hai TW, Liu F, Coukos WJ and Green MR: Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 3: 2083-2090, 1989. (Pubitemid 20023233)
34. Rehfuss RP, Walton KM, Loriaux MM and Goodman RH: The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A. J Biol Chem 266: 18431-18434, 1991.
35. Foulkes NS, Borrelli E and Sassone-Corsi P: CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64: 739-749, 1991. (Pubitemid 121001161)
36. Cowell IG, Skinner A and Hurst HC: Transcriptional repression by a novel member of the bZIP family of transcription factors. Mol Cell Biol 12: 3070-3077, 1992.
37. Karpinski BA, Morle GD, Huggenvik J, Uhler MD and Leiden JM: Molecular cloning of human CREB-2: an ATF/CREB transcription factor that can negatively regulate transcription from the cAMP response element. Proc Natl Acad Sci USA 89: 4820-4824, 1992.
38. Hagiwara M, Brindle P, Harootunian A, Armstrong R, Rivier J, Vale W, Tsien R and Montminy MR: Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol 13: 4852-4859, 1993. (Pubitemid 23220391)